p53 Unleashes Endogenous Retroviruses to Tackle Tumors: Study
p53 Unleashes Endogenous Retroviruses to Tackle Tumors: Study
New experiments suggest the famous tumor-suppressing protein uses viral elements lingering in the genome to get cancerous cells to announce their presence to the immune system.
p53 Unleashes Endogenous Retroviruses to Tackle Tumors: Study
p53 Unleashes Endogenous Retroviruses to Tackle Tumors: Study

New experiments suggest the famous tumor-suppressing protein uses viral elements lingering in the genome to get cancerous cells to announce their presence to the immune system.

New experiments suggest the famous tumor-suppressing protein uses viral elements lingering in the genome to get cancerous cells to announce their presence to the immune system.

cancer drugs
Microscopic Robots Deliver Drugs to the Brain
Microscopic Robots Deliver Drugs to the Brain
Asher Jones | Mar 30, 2021
Researchers turned white blood cells called neutrophils into drug-smuggling “neutrobots,” which penetrated the blood-brain barrier to treat brain cancer in mice.
José Baselga, Renowned Oncologist, Dies at 61
José Baselga, Renowned Oncologist, Dies at 61
Asher Jones | Mar 22, 2021
The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.
Pioneering Cancer Researcher Emil Freireich Dies at 93
Pioneering Cancer Researcher Emil Freireich Dies at 93
Asher Jones | Feb 5, 2021
The oncologist developed lifesaving childhood leukemia treatments and revolutionized chemotherapy.
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Harnessing Stem Cell–Like T Cells to Better Fight Cancer
Daniel E. Speiser and Werner Held | Jul 13, 2020
Better understanding the CD8+ T cells already present in tumors could be key to making immunotherapies work for more patients.
Infographic: Researchers Take Aim at Cancer Evolution
Infographic: Researchers Take Aim at Cancer Evolution
Catherine Offord | Apr 1, 2020
Strategies to trick, manipulate, and direct the evolution of tumors
Biochemist Stanley Cohen Dies
Biochemist Stanley Cohen Dies
Catherine Offord | Feb 10, 2020
The Vanderbilt University professor was awarded a Nobel Prize for his discovery of epidermal growth factor.
Cancer Cells Increase DNA Mutations to Evade Treatment
Cancer Cells Increase DNA Mutations to Evade Treatment
Abby Olena | Nov 7, 2019
Colorectal tumor cells limit their DNA repair in response to a targeted therapy, giving them a greater chance to develop resistance to the drug.
Cancer Drugs in Development May Be Targeting Wrong Proteins
Cancer Drugs in Development May Be Targeting Wrong Proteins
Shawna Williams | Sep 12, 2019
A study of 11 drugs now in clinical trials suggests they do kill cancer cells—but through a different mechanism than indicated in previous research.
Genetically Personalized Fruit Flies Screen for Cancer Drugs
Genetically Personalized Fruit Flies Screen for Cancer Drugs
Ruth Williams | May 22, 2019
Fly avatars bearing multiple genetic changes akin to those of a cancer patient lead to a tailor-made treatment that has shrunk the patient’s tumors.
John Mendelsohn, Former MD Anderson Cancer Center President, Dies
John Mendelsohn, Former MD Anderson Cancer Center President, Dies
Ashley Yeager | Jan 10, 2019
The scientist and clinician helped develop a new form of cancer therapy, using a monoclonal antibody to treat head, neck, colorectal, and lung cancers.
Eli Lilly Will Buy Loxo Oncology for $8 Billion
Eli Lilly Will Buy Loxo Oncology for $8 Billion
Ashley Yeager | Jan 8, 2019
Loxo focuses on cancer treatments based on tumor genetics, which will contribute to Lilly’s push in the cancer drug space.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Fecal Transplant Heals Colitis Caused by Immunotherapy
Fecal Transplant Heals Colitis Caused by Immunotherapy
Anna Azvolinsky | Nov 12, 2018
A case study of two patients with advanced cancer shows it might be possible to avoid a common and severe side effect of immunotherapy treatment.
Infographic: Cancer Drug Pairings
Infographic: Cancer Drug Pairings
Anna Azvolinsky | Mar 31, 2018
Researchers use several different strategies to deliver a one-two punch.
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Sanofi and Celgene Spend $20 Billion in Major Biotech Acquisitions
Katarina Zimmer | Jan 22, 2018
Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.
AbbVie Wins Bidding War for Cancer Drugmaker
AbbVie Wins Bidding War for Cancer Drugmaker
Bob Grant | Mar 5, 2015
The pharmaceutical firm beat out a host of potential suitors, Johnson & Johnson among them, to strike a $21 billion deal with Pharmacyclics.
Lavish Spending at MD Anderson
Lavish Spending at MD Anderson
Kate Yandell | May 28, 2013
The public cancer center is criticized for allegedly devoting at least $1.5 million to remodeling an executive suite.
Spinning Clinical Trials
Spinning Clinical Trials
Dan Cossins | Jan 16, 2013
Results of breast cancer drug trials are regularly spun to conceal bias and make the drugs seem more effective or less toxic than they really are.
$18M Grant to Be Re-reviewed
Jef Akst | Jun 1, 2012
A Texas cancer institute is taking a second look at the largest grant it ever awarded after concerns were raised that the proposal never received proper scientific review.